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Abstract
Background Family screening for hypertrophic car-
diomyopathy (HCM) is based on genetic testing and
clinical evaluation (maximal left ventricular wall
thickness (MWT) ≥15mm, or ≥13mm in first-de-
gree relatives of HCM patients). The aim of this study
was to assess the effect of gender and body size on
diagnosis of HCM and prediction of clinical outcome.
Methods This study includes 199 genotype-positive
subjects (age 44± 15 years, 50% men) referred for
cardiac screening. Gender-specific reference values
for MWT indexed by body surface area (BSA), height
and weight were derived from 147 healthy controls.
Predictive accuracy of each method for HCM-related
events was assessed by comparing areas under the
receiver operating characteristic curves (AUC).
Results Men had a higher absolute, but similar BSA-
and weight-indexed MWT compared with women
(14.0± 3.9mm vs 11.5± 3.8mm, p<0.05; 6.8±
2.1mm/m2 vs 6.6± 2.4mm/m2; 0.17± 0.06mm/kg vs
0.17± 0.06mm/kg, both p> 0.05). Applying BSA- and
weight-indexed cut-off values decreased HCM di-
agnoses in the study group (48% vs 42%; 48% vs
39%, both p<0.05), reclassified subjects in the largest,
lightest and heaviest tertiles (≥2.03m2: 58% vs 45%;
≤70kg: 37% vs 46%; ≥85kg: 53% vs 25%, all p< 0.05)
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and improved predictive accuracy (AUC 0.76 [95% CI
0.69–0.82] vs 0.78 [0.72–0.85]; and vs 0.80 [0.74–0.87];
both p< 0.05).
Conclusions In genotype-positive subjects referred for
family screening, differences in MWT across gender
are mitigated after indexation by BSA or weight. In-
dexation decreases the prevalence of HCM, particu-
larly in larger men, and improves the predictive accu-
racy for HCM-related events.
Keywords Hypertrophic cardiomyopathy · Family
screening · Gender · Body surface area · Prediction
Introduction
Hypertrophic cardiomyopathy (HCM) is the most
prevalent inherited cardiac disease, with a prevalence
of 0.2–0.5% in the general population [1]. Because
What’s New?
 Observed differences in maximal wall thickness
across gender are mitigated when correcting for
body size.
 Correcting for body size decreases the number of
hypertrophic cardiomyopathy (HCM) diagnoses,
particularly in larger men. This finding may par-
tially explain the male predominance often seen
in HCM cohorts.
 Correcting maximal wall thickness for body size
and applying specific cut-off values improves the
predictive accuracy for HCM-related events, sug-
gesting superior patient identification.
 This is the first study assessing the potential role
of body size indexation in the context of diag-
nosing HCM.
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of its familial character, and to prevent potentially
life-threatening complications, family screening is
advised in first-degree relatives of HCM patients.
Contemporary family screening is based on genetic
testing and clinical evaluation (maximal left ventricu-
lar wall thickness (MWT) ≥15mm, or ≥13mm in first-
degree relatives of HCM patients) [2]. These absolute
echocardiographic cut-off values ignore the fact that
subjects differ in gender and size. Indexation is ad-
vocated in various echocardiographic measurements,
particularly left ventricular and left atrial dimensions,
and in the diagnosis of aortic dilatation [3, 4]. How-
ever, the role of body size indexation in HCM is
unknown. The aims of this study are to assess the ef-
fect of gender and body size on the diagnosis of HCM
in genotype-positive relatives, to compare this with
normal values derived from healthy volunteers and




This study included 199 first-degree genotype-positive
relatives of HCM patients (99 men, mean age 44 years,
range 17–82 years) referred for cardiac screening be-
tween 1995 and 2018. As all subjects had first-degree
relatives with HCM, the diagnosis of HCM was based
on an MWT ≥13mm not explained by loading con-
ditions or metabolic or mitochondrial disorders, in
accordance with the guidelines [2]. The study con-
forms to the Declaration of Helsinki. All subjects gave
informed consent and institutional review board ap-
proval was obtained.
Genetic analysis
Genetic counselling and testing is routinely offered
to HCM patients visiting our cardiogenetic outpatient
clinic, and is described previously [5]. After detec-
tion of a pathogenic mutation in the proband, cas-
cade genetic screening is offered to first-degree rela-
tives, targeting themutation identified in the proband.
Genotype-positive relatives are then referred for car-
diac screening.
Clinical assessment
Clinical assessment included physical examination
and transthoracic echocardiography (TTE). Body sur-
face area (BSA) was calculated with the DuBois &
DuBois formula [6]. TTE studies were analysed in
accordance with the guidelines [2, 4]. Left ventricular
wall thickness was measured in the parasternal long-
axis view at or immediately below the level of the mi-
tral valve leaflet tips, or in the parasternal short-axis
view, whenever maximal wall thickness was localised
to regions other than the basal segments.
Control group
Gender-specific normal values were derived from 147
healthy volunteers (73 men, mean age 45 years). All
subjects were enrolled in 2014–2015 as part of a pre-
viously published study conducted at our centre [7].
In short, healthy volunteers between 20–72 years un-
derwent regular clinical assessment at our outpatient
clinic, including TTE and height and weight mea-
surement. Exclusion criteria were previous or existing
cardiovascular disease; presence of hypertension, di-
abetes mellitus or hypercholesterolaemia; systemic
disease or medication potentially influencing cardiac
function; or cardiac abnormalities at physical exam-
ination or present on electrocardiogram. MWT was
measured by an experienced sonographer (DB) and
was divided by BSA for each subject. A cut-off value
was derived from the mean MWT/BSA plus two stan-
dard deviations. This was repeated for height and
weight separately.
Outcome measures
As the diagnosis of HCM lacks a true gold standard,
HCM-related endpoints were considered surrogate
markers of disease presence, allowing comparison
of the diagnostic accuracy of the different meth-
ods. These included HCM-related mortality, cardiac
transplantation, implantable cardioverter-defibrilla-
tor (ICD) implantation and septal reduction therapy.
Mortality was considered HCM-related in sudden car-
diac death or following heart failure, stroke or an
HCM intervention. Sudden cardiac death was defined
as (1) instantaneous, unexpected death in patients
who were previously stable, or nocturnal death with
no history of worsening symptoms; (2) death fol-
lowing resuscitation after cardiac arrest; or (3) death
following appropriate ICD intervention. Septal reduc-
tion therapy and ICD implantations were indicated
in accordance with guideline recommendations [2].
Mortality data was retrieved from municipal personal
records databases.
Statistical analysis
Values were expressed as mean± standard deviation,
median [interquartile range] or number (%). Contin-
uous variables were compared using Student’s t-test
or Mann-Whitney U test and categorical data were
compared using Pearson’s χ2 test. Proportions of HCM
diagnoses were compared using McNemar’s test. The
sensitivity and specificity of the different methods
were assessed using receiver operating characteristic
(ROC) curves, and their predictive accuracy for HCM-
related events was analysed by comparing the areas
under the curve (AUC), using the De Long method for
paired data [8]. All analyses were two-tailed and per-
formed using SPSS version 22 (IBM Corp., Armonk,
New York) and the pROC package for R version 3.4.1
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Table 1 Baseline characteristics of control and study group according to gender
Variables Control group Study group
Overall Male Female Overall Male Female










Age, y 45± 14 44± 14 45± 14 0.582 44± 15 43± 14 46± 15 0.105 0.728
Weight, kg 75± 13 82± 11 69± 9 <0.001 78± 16 87± 14 70± 13 <0.001 0.043
Height, cm 175± 9 181± 10 169± 10 <0.001 174± 10 182± 7 167± 6 <0.001 0.623
BSA, m2 1.89± 0.19 2.03± 0.15 1.76± 0.1 <0.001 1.92± 0.23 2.07± 0.17 1.78± 0.18 <0.001 0.189
MWT, mm 9.2± 1.7 9.9± 1.6 8.6± 1.6 <0.001 12.8± 4.0 14.0± 3.9 11.5± 3.8 <0.001 <0.001
MWT/BSA,
mm/m2
4.9± 0.9 4.9± 0.8 4.9± 0.9 0.939 6.7± 2.3 6.8± 2.1 6.6± 2.4 0.358 <0.001
MWT/weight,
mm/kg
0.13± 0.02 0.12± 0.02 0.13± 0.03 0.030 0.17± 0.06 0.17± 0.06 0.17± 0.06 0.907 <0.001
MWT/height,
mm/m
5.3± 0.98 5.5± 0.96 5.01± 0.97 0.019 7.3± 2.3 7.8± 2.2 6.9± 2.3 0.012 <0.001
Data are expressed as mean± standard deviation
BSA body surface area; MWT maximal wall thickness
(https://cran.r-project.org/) [9]. P-values <0.05 were
considered statistically significant.
Results
Baseline characteristics for controls and study pa-
tients are presented in Tab. 1. The groups were of
similar age, height and BSA, but had different mean
weight and MWT. In the control group, mean MWT
was significantly higher in men. Men were taller,
heavier and had a higher BSA. The cut-off values for
MWTBSA, MWTweight and MWTheight were 6.51mm/m2,
0.16mm/kg and 7.38mm/m for men and 6.68mm/m2,
0.18mm/kg and 7.03mm/m for women.
Reclassification of subjects
In the study group, 56 (57%)men and 40 (40%) women
were diagnosed with HCM according to the absolute
cut-off. The impact of indexed cut-offs on the pro-
portion of HCM diagnoses is illustrated in Fig. 1. After
BSA indexation, the prevalence of HCM decreased sig-
nificantly, with 14 subjects (8 men) reclassified as no
HCM, and 4 subjects (1 man) reclassified as HCM. The
decrease in diagnoses remained significant for men
separately, but not for women. A similar pattern was
seen after indexation by weight, but not after indexa-
tion by height. Subjects reclassified as no HCM after
indexation by BSA had a mean BMI of 28.8± 3.3kg/m2,
compared with 21.3± 2.3kg/m2 for subjects reclassi-
fied as HCM and 25.6± 4.1kg/m2 for non-reclassified
subjects.
Effect of body size on diagnosis of HCM
Subjects were stratified by BSA tertiles and the preva-
lence of HCM using the conventional and BSA-in-
dexed method was compared in each tertile (Fig. 2a).
Larger patients were diagnosed less often (59% vs 47%,
p= 0.008). Subjects in the lowest weight tertile were
diagnosed less often after indexation by weight. The
opposite was true for the highest tertile (normal vs
indexed, ≤70kg: 37% vs 46%, p=0.03; ≥85kg: 54% vs
26%, p< 0.001, Fig. 2b). No significant changes were
seen after indexation by height (Fig. 2c).
Clinical outcome
In the study group, 23 events occurred in 19 patients,
over a median follow-up of 5.8 [2.3–8.8] years. Sudden
cardiac death occurred in 2 patients and there was
1 cardiac transplantation. Five patients underwent
myectomy and ICDs were implanted in 15 patients.
There were no events in patients reclassified from
HCM to no HCM and vice versa. Predictive accuracy
for HCM-related events improved significantly after
indexation by BSA and weight (AUC for MWT: 0.757
[95% CI 0.69–0.82]; MWTBSA: 0.785 [95% CI 0.72–0.85],
Fig. 1 Prevalence of HCM before and after indexation strat-
ified by gender. Indexation by BSA or weight significantly
decreased diagnoses in men and in the total group. As-
terisk denotes significant differences between proportions.
HCM hypertrophic cardiomyopathy, MWTmaximal wall thick-
ness, BSA body surface area
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Fig. 2 Prevalence of HCM diagnoses in study group, after
indexation according to a BSA, b weight and c height. Signifi-
cant differences in proportions of HCM were seen in the high-
est BSA tertile, after indexation for BSA, and in the lowest and
highest weight tertiles after indexation for weight. Asterisk de-
notes significant differences between proportions. BSA body
surface area, HCM hypertrophic cardiomyopathy, MWT maxi-
mal wall thickness
p< 0.05; MWTweight: 0.804 [95% CI 0.74–0.87], p< 0.01,
Fig. 3), but was similar after indexation by height
(MWTheight: 0.768 [95% CI 0.71–0.83], p=0.2). Index-
ation by BSA, weight and height increased specificity
from 0.57 to 0.62, 0.66 and 0.59 respectively, whilst
sensitivity was 0.947 for all methods.
Discussion
The main findings of this study are that in genotype-
positive subjects presented for cardiac screening:
1) mean MWT is higher in men than in women,
and that this difference is nullified after indexation
by BSA or weight; 2) body size influences the di-
agnosis of HCM, with the largest and heaviest sub-
jects being diagnosed significantly less often after
BSA- or weight-indexation and application of gen-
der-specific reference values obtained in healthy
controls, with the reverse being true for the light-
est tertile; 3) weight is the primary determinant of
these differences; and 4) indexation by BSA or weight
augments the predictive accuracy for HCM-related
events, suggesting superior patient identification us-
ing gender-specific cut-off values for MWTBSA (men:
6.51mm/m2, women: 6.68mm/m2) and MWTweight
(men: 0.16mm/kg, women: 0.18mm/kg), instead of
the conventional cut-off.
Indexation is increasingly being used in the context
of cardiac disease [3, 4]. Left ventricular mass, calcu-
lated using septal and posterior wall dimensions, is
routinely reported after correcting for BSA. Neverthe-
less, there is no mention of body size when report-
ing wall thickness alone. In this cohort, the diagnosis
of HCM was predominantly altered in patients with
a high BSA, but also in the lightest and heaviest group
when stratifying by weight alone. The decrease of di-
agnoses in men, being taller and heavier than women,
supports the notion that body size matters in diagnos-
ing HCM.
Furthermore, our results imply that these differ-
ences are driven by weight variations, which is illus-
trated by the effects of indexation by BSA and weight
and the lack thereof when indexing by height. Indexa-
tion by weight reclassified a significant number of the
lightest and heaviest subjects, and subjects reclassi-
fied as no HCM were predominantly obese. Left ven-
tricular enlargement is a well-recognised physiologi-
cal adaptation aimed at optimising stroke volume to
compensate for an increased oxygen demand [10–13],
and is also seen in HCM [14]. Olivotto et al. studied
275 HCM patients (age 48± 14 years; 70% male) and
found that BMI was independently associated with
magnitude of hypertrophy, defined as an increase in
likelihood of having a left ventricular mass in the high-
est quartile (>120g/m2) [14].
The autosomal dominant inheritance pattern of
HCM implies an equal gender distribution. How-
ever, many cohorts illustrate a male predominance
[15–20], bringing forth potential explanations ranging
from delays in clinical presentation to differences in
gene expression and sex hormone receptor levels [18].
In this cohort, less men, but not women, were diag-
nosed with HCM after indexation, suggesting that
applying non-indexed cut-off values overestimates
the prevalence of HCM in men. Moreover, in the con-
trol group, MWT was higher in men than in women.
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Fig. 3 Receiver operat-
ing characteristic curves
illustrating predictive ac-
curacy of all diagnostic
methods for HCM-related
events. A significant in-
crease in the AUC was
seen using BSA- or weight-
indexed values: difference
between areas was 0.028
[95% CI 0.005–0.051] for
MWT and MWTBSA, 0.047
[0.017–0.078] for MWT
and MWTweight and 0.011
[–0.006–0.028] for MWT
and MWTheight. HCM hy-
pertrophic cardiomyopa-
thy, AUC area under the
curve, BSA body surface
area, MWT maximal wall
thickness
Although it is unlikely that this finding is the primary
cause of the observed gender disparity, especially in
light of the aforementioned hypotheses, it does offer
a partial explanation.
Additionally, gender disparities are reported when
comparing disease severity and outcome [15, 21–25],
generally in favour of men. In a cohort of 27 women
and 44 men, Nijenkamp et al. demonstrated that tis-
sue samples of women who underwent myectomy
showed decreased expression of phospholamban
(PLN) and sarco/endoplasmic reticulum Ca2+ ATPase
(SERCA2), more compliant titin and more fibrosis
[22]. Absolute MWT, left ventricular and left atrial di-
ameter were similar across gender, but BSA-corrected
values were higher in women. Although we are unable
to corroborate these results, our findings do support
indexation when assessing gender differences.
The clinical relevance of indexation in HCM is
demonstrated by the augmented predictive accuracy
for HCM-related events after indexation for BSA or
weight, by improving specificity without sacrificing
sensitivity, indicating proper identification of HCM
patients. It is reassuring that no endpoints occurred
in HCM patients reclassified as no HCM after a me-
dian follow-up of 5.8 years. To our knowledge, this is
the first study demonstrating the value of indexation
in HCM, albeit in a single centre and with a mod-
est size and low event rate. As the clinical spectrum
of HCM is expanding with the advent of advanced
genetic testing and imaging, the prevalence of HCM
will increase, emphasising the importance of correct
patient identification as a means of decreasing the
burden on health care systems [1, 26, 27], by virtue
of less frequent follow-up and a decreased need for
cardiac monitoring, exercise testing and imaging.
Additionally, a reduction in HCM diagnoses has the
potential to preclude patients from unnecessary (ex-
ercise) restrictions, simultaneously decreasing their
psychological burden. Future studies in index patients
(i.e. those requiring MWT measurement ≥15mm) will
potentially decrease HCM diagnoses in that group,
leading to less (unnecessary) genetic testing and fam-
ily screening.
This study has several limitations. In the first place,
the inherent limitations of retrospective studies ap-
ply here, although some of these limitations were at-
tenuated by a dedicated assessment of MWT in con-
trols. Moreover, scaling cardiac size using BSA in pa-
tients with hypertensive left ventricular hypertrophy
has been shown to underestimate the prevalence of
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left ventricular hypertrophy in obese individuals [28],
raising the possibility that the same problem occurs
in our data. As there is a paucity of data on the rela-
tionship between body size and cardiac dimensions in
the context of HCM, we cannot exclude the influence
of obesity on our results and acknowledge that the
concept of scaling MWT to body size requires further
attention before it can be incorporated into clinical
practice. Furthermore, body size is only one factor
potentially influencing HCM diagnoses, with an in-
dividual’s prior chance of HCM likely depending on
several other components (e.g. hypertension, engag-
ing in strenuous physical activity). This includes inter-
reader and intra-reader variability, which can poten-
tially influence HCM diagnoses in our data as well as
in clinical practice. Finally, although mortality data
was complete for all patients, we cannot exclude the
possibility of other events (mainly ICD implantations)
occurring in other centres.
In conclusion, in genotype-positive subjects re-
ferred for cardiac screening, differences in MWT
across gender are mitigated after correcting for body
size, especially body weight. The effect of body size
on the diagnosis of HCM is demonstrated by the re-
classification of mainly male subjects when indexing
by BSA or body weight. The improved predictive
accuracy for HCM-related events after indexation by
BSA or weight suggests that correcting for body size
has a potential role in the diagnosis of HCM.
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